Empagliflozin Suppresses the Differentiation/Maturation of Human Epicardial Preadipocytes and Improves Paracrine Secretome Profile
Source : https://www.sciencedirect.com/science/article/pii/S2452302X23002280?via=ihub
Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce epicardial adipose tissue (EAT) in humans, enhancing cardioprotective effects on heart failur...
Empagliflozin suppresses human epicardial preadipocyte differentiation/maturation, likely inhibiting epicardial adipogenesis and improving the paracrine secretome profile of EAT, particularly by regulating IL6 expression.
The SGLT2 Inhibitor Empagliflozin Attenuates Atherosclerosis Progression by Inducing Autophagy
Source : https://link.springer.com/article/10.1007/s13105-023-00974-0
Cardiovascular disease due to atherosclerosis is one of the leading causes of death worldwide; however, the underlying mechanism has yet to be defined. The sodium-dependent glucose transporter 2 inhibitor (SGLT2i)...
Empagliflozin activates autophagy through the AMPK signaling pathway to delay the evolution of atherosclerosis, indicating that it may represent a new and effective drug for the clinical treatment of atherosclerosis.
SGLT2 Inhibitors for Patients With Heart Failure With Preserved Ejection Fraction in China: a Cost-Effectiveness Study
Source : https://www.frontiersin.org/articles/10.3389/fphar.2023.1155210/full
Background: The potential benefits of intervention with empagliflozin or dapagliflozin for patients with heart failure with preserved ejection fraction (HFpEF) were first demonstrated in the EMPEROR-Preserved and DELIVER studies.
In Chinese healthcare, the interventions (empagliflozin or dapagliflozin) for HFpEF were more cost-effective than the comparators. Our study has provided a quantitative evaluation of the costs and benefits of such interventions for a lifetime using the model.
Empagliflozin Improves Circulating Vascular Regenerative Cell Content in People Not Living With Diabetes But With Cardiovascular Risk Factors
Source : https://pubmed.ncbi.nlm.nih.gov/37773589/
SGLT2 inhibitors have been reported to reduce cardiovascular events and heart failure in people with and without diabetes. These medications have been shown to counter regenerative cell exhaustion in the...
Empagliflozin promoted the recovery of multiple circulating pro-vascular cell subsets in people without diabetes suggesting that the cardiovascular benefits of SGLT2 inhibitors may be attributed in part to the attenuation of vascular regenerative cell exhaustion that is independent of diabetes status.
What is the exact mechanism which results in the clinical outcomes, and Heart Failure patients with SGPT2 inhibitors?
-
Heart Failure Connect2yrThanks so much for this intriguing question. Numerous mechanisms likely underlie the cardioprotective effects of SGLT2. The following excerpt from JACC: Basic to Translational Science outlines them as follows: “These include Show More
Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315190/
Recent clinical trials have shown that sodium glucose co-transport 2 (SGLT2) inhibitors have dramatic beneficial cardiovascular outcomes. These include a reduced incidence of cardiovascular death and heart failure hospitalization in Show More